Literature DB >> 21192341

Targeting the oncogenic role of miRNA in human cancer using naturally occurring compounds.

Stuart A Rushworth1.   

Abstract

Micro-RNAs (miRNAs) are small RNA molecules that regulate the expression of genes involved in development, growth, proliferation and apoptosis. In cancer several miRNAs have been functionally classified as oncogenes or tumour suppressers or act to regulate transcription factors, like nuclear factor kappa B and NF-E2–related factor 2, in cancers such as leukaemia, breast and colorectal. Therefore, it has been proposed that manipulating miRNA regulation may be a novel avenue for developing efficient therapies against cancer. In this issue, Li and colleagues describe a novel way of targeting miRNA, by using a naturally occurring anti-cancer compound found in mistletoe which they showed to down-regulate miR-135a&b, which target the 3' untranslated region of adenomatous polyposis coli gene, the inactivation of which is a major initiating event in colorectal tumourigenesis. This commentary aims to discuss the regulatory mechanisms of miRNA synthesis and the potential outcomes for using naturally occurring compounds antioxidants or cellular antioxidant pathways to target miRNA for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21192341      PMCID: PMC3031056          DOI: 10.1111/j.1476-5381.2010.01075.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Down-regulation of some miRNAs by degrading their precursors contributes to anti-cancer effect of mistletoe lectin-I.

Authors:  Lin-Na Li; Hua-Dong Zhang; Run Zhi; Shou-Jun Yuan
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

2.  Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Brett Adair; Hansjuerg Alder; Emeric Limagne; Cristian Taccioli; Manuela Ferracin; Dominique Delmas; Norbert Latruffe; Carlo M Croce
Journal:  Carcinogenesis       Date:  2010-07-09       Impact factor: 4.944

3.  Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.

Authors:  Yoshimasa Saito; Gangning Liang; Gerda Egger; Jeffrey M Friedman; Jody C Chuang; Gerhard A Coetzee; Peter A Jones
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

4.  microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease.

Authors:  Carolyn Sangokoya; Marilyn J Telen; Jen-Tsan Chi
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

5.  A MicroRNA targeting dicer for metastasis control.

Authors:  Graziano Martello; Antonio Rosato; Francesco Ferrari; Andrea Manfrin; Michelangelo Cordenonsi; Sirio Dupont; Elena Enzo; Vincenza Guzzardo; Maria Rondina; Thomas Spruce; Anna R Parenti; Maria Grazia Daidone; Silvio Bicciato; Stefano Piccolo
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

6.  Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma.

Authors:  Simion Chiosea; Elena Jelezcova; Uma Chandran; Marie Acquafondata; Teresa McHale; Robert W Sobol; Rajiv Dhir
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  HO-1 underlies resistance of AML cells to TNF-induced apoptosis.

Authors:  Stuart A Rushworth; David J MacEwan
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

8.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

9.  Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells.

Authors:  Wing Pui Tsang; Tim Tak Kwok
Journal:  J Nutr Biochem       Date:  2009-03-09       Impact factor: 6.048

  9 in total
  8 in total

1.  Understanding the role of miRNA in regulating NF-κB in blood cancer.

Authors:  Stuart A Rushworth; Megan Y Murray; Lawrence N Barrera; Sally-Anne Heasman; Lyubov Zaitseva; David J Macewan
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

2.  MicroRNA-96 promotes myocardial hypertrophy by targeting mTOR.

Authors:  Xuemei Sun; Chunlai Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Suffocating cancer: hypoxia-associated epimutations as targets for cancer therapy.

Authors:  C Thirlwell; Lke Schulz; Hk Dibra; S Beck
Journal:  Clin Epigenetics       Date:  2011-12-05       Impact factor: 6.551

4.  Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may target DUSP1.

Authors:  Dou Dou; Yan-Fen Shi; Qing Liu; Jie Luo; Ji-Xi Liu; Meng Liu; Ying-Ying Liu; Yuan-Liang Li; Xu-Dong Qiu; Huang-Ying Tan
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

5.  Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric neuroendocrine neoplasms.

Authors:  Dou Dou; Xiao-Kou Li; Qi-Sheng Xia; Ying-Ying Chen; Yuan-Liang Li; Chao Wang; Zhi-Rong Qi; Huang-Ying Tan
Journal:  BMC Gastroenterol       Date:  2021-04-23       Impact factor: 3.067

Review 6.  MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy.

Authors:  Ming Hong; Ning Wang; Hor Yue Tan; Sai-Wah Tsao; Yibin Feng
Journal:  Cancers (Basel)       Date:  2015-08-24       Impact factor: 6.639

7.  Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.

Authors:  Nguyen Thi Thuy Phuong; Sang Kyum Kim; Ji Hye Im; Jin Won Yang; Min Chang Choi; Sung Chul Lim; Kwang Yeol Lee; Young-Mi Kim; Jeong Hoon Yoon; Keon Wook Kang
Journal:  Oncotarget       Date:  2016-03-22

Review 8.  Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.

Authors:  Yasamin Davatgaran-Taghipour; Salar Masoomzadeh; Mohammad Hosein Farzaei; Roodabeh Bahramsoltani; Zahra Karimi-Soureh; Roja Rahimi; Mohammad Abdollahi
Journal:  Int J Nanomedicine       Date:  2017-04-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.